Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Advancing Care in Pediatric Plaque Psoriasis: Emerging Treatments and Management Strategies : Episode 8
Opinion
Video
Exploring the Role of MOA and PDE4 Pathways in Pediatric Patients with Plaque Psoriasis
Author(s):
Key Takeaways
- PDE4 inhibitors modulate inflammatory responses by increasing intracellular cAMP levels, reducing pro-inflammatory cytokine production.
- These agents offer a targeted approach, potentially minimizing side effects compared to traditional therapies.
Panelists discuss how phosphodiesterase-4 (PDE4) inhibitors, with their ability to modulate inflammatory pathways, hold promise as therapeutic targets for immune-mediated diseases like pediatric plaque psoriasis, offering unique benefits by potentially reducing inflammation with a favorable safety profile for pediatric patients.
Video content above is prompted by the following:
- In light of the shifting treatment landscape, can you shed light on phosphodiesterase inhibitors-4 (PDE4), their nature, and why they hold promise as therapeutic targets for immune-mediated diseases like PP?
- How might its mechanism of action provide unique benefits for pediatric patients?
Related Videos
Related Content
